What is the official website of Intertek Melbourn ?

The official website of Intertek Melbourn is http://www.intertek.com/pharmaceutical/melbourn/.

What is Intertek Melbourn's cybersecurity risk score?

Intertek Melbourn has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Intertek Melbourn experienced?

According to Rankiteo, Intertek Melbourn currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Intertek Melbourn been affected by any supply chain cyber incidents ?

According to Rankiteo, Intertek Melbourn has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Intertek Melbourn have SOC 2 Type 1 certification ?

According to Rankiteo, Intertek Melbourn is not certified under SOC 2 Type 1.

Does Intertek Melbourn have SOC 2 Type 2 certification ?

According to Rankiteo, Intertek Melbourn does not hold a SOC 2 Type 2 certification.

Does Intertek Melbourn comply with GDPR ?

According to Rankiteo, Intertek Melbourn is not listed as GDPR compliant.

Does Intertek Melbourn have PCI DSS certification ?

According to Rankiteo, Intertek Melbourn does not currently maintain PCI DSS compliance.

Does Intertek Melbourn comply with HIPAA ?

According to Rankiteo, Intertek Melbourn is not compliant with HIPAA regulations.

Does Intertek Melbourn have ISO 27001 certification ?

According to Rankiteo,Intertek Melbourn is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Intertek Melbourn operate in ?

Intertek Melbourn operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Intertek Melbourn have ?

Intertek Melbourn employs approximately 105 people worldwide.

Does Intertek Melbourn own any subsidiaries ?

Intertek Melbourn presently has no subsidiaries across any sectors.

How many LinkedIn followers does Intertek Melbourn have ?

Intertek Melbourn's official LinkedIn profile has approximately 3,458 followers.

What is the NAICS classification code for Intertek Melbourn ?

Intertek Melbourn is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Intertek Melbourn have a Crunchbase profile ?

No, Intertek Melbourn does not have a profile on Crunchbase.

Does Intertek Melbourn have a LinkedIn profile ?

Yes, Intertek Melbourn maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/intertek-melbourn.

How many cybersecurity incidents has Intertek Melbourn experienced ?

As of August 25, 2026, Rankiteo reports that Intertek Melbourn has not experienced any cybersecurity incidents.

How many peer or competitor companies does Intertek Melbourn have ?

Intertek Melbourn has an estimated 5,737 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Intertek Melbourn

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Intertek Melbourn Vendor Cyber Rating & Cyber Score

intertek.com

Add Your Compliance Badge

A leading provider of pharmaceutical analysis and formulation support with 30+ years of experience in inhaled product development and Good Manufacturing Practice (GMP) compliant analytical testing and stability storage services. We have a reputation for providing outstanding and responsive customer service. Previously known as Melbourn Scientific Ltd, the laboratory, based near Cambridge UK, was acquired by Intertek in 2013. We opened a second facility in 2015 and another in 2019 leading to further expansion which has doubled our laboratory footprint. We have specialist skills and experience in analytical testing and formulation for inhaled and intranasal products as well as all other dosage forms for healthcare products. Clients include

Intertek Melbourn A.I CyberSecurity Scoring

Scoring History

Intertek Melbourn

Intertek Melbourn CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Intertek Melbourn Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Intertek Melbourn

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Intertek Melbourn in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Intertek Melbourn in 2026.

Incident Types Intertek Melbourn vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Intertek Melbourn in 2026.

Incident History - Intertek Melbourn (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Intertek Melbourn Subsidiaries

Intertek Melbourn

Pharmaceutical Manufacturing

Website: http://www.intertek.com/pharmaceutical/melbourn/

Company Size: 105

IntertekInternational Trade and Development

Intertek BrazilInternational Trade and Development

Intertek BangladeshInternational Trade and Development

Intertek LatinoaméricaInternational Trade and Development

Intertek Middle EastInternational Trade and Development

Intertek FranceInternational Trade and Development

Intertek EnergyOil and Gas

Professional Service Industries, Inc. (PSI)Civil Engineering

Intertek SpainInternational Trade and Development

Intertek Business AssuranceInternational Trade and Development

Intertek ElectricalAppliances, Electrical, and Electronics Manufacturing

Intertek Agriculture & FoodFood and Beverage Manufacturing

Intertek AssurisConsumer Goods

Intertek SustainabilityInternational Trade and Development

Intertek Greater ChinaInternational Trade and Development

Intertek Softlines and HardlinesRetail

Intertek SwedenInternational Trade and Development

Intertek Transportation TechnologiesMotor Vehicle Manufacturing

Intertek Pharmaceutical ServicesPharmaceutical Manufacturing

Intertek DeutschlandBusiness Consulting and Services

Intertek MineralsMining

Intertek Government and Trade ServicesInternational Trade and Development

Intertek Chemicals & Materials - Laboratory Testing ServicesChemical Manufacturing

Intertek Cosmetics & Consumer HealthcareRetail Health and Personal Care Products

Intertek LintecInternational Trade and Development

Loading…

Intertek Melbourn Similar Companies

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Loading…

NEWS

Intertek Melbourn CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-78147

SUMMARY

A vulnerability was found in ggml-org llama.cpp bec4772f6. The impacted element is the function deserialize_tensor of the file ggml/src/ggml-rpc/ggml-rpc.cpp of the component ggml-RPC Server. Performing a manipulation of the argument op/op_params results in deserialization. The attack may be initiated remotely. This vulnerability is distinct from CVE-2026-34159 (GHSA-j8rj-fmpv-wcxw, PR #20908), which only added a buffer==nullptr rejection in create_node() and does not validate op or op_params. The reported GitHub issue was closed automatically due to inactivity.

Published

Date2026-08-23

Updated

Date2026-08-23

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

CVE-2026-78145

SUMMARY

A vulnerability has been found in CTFd up to 3.8.4. The affected element is the function _is_safe_url of the file CTFd/utils/validators/__init__.py. Such manipulation of the argument Next leads to open redirect. The attack can be launched remotely. The exploit has been disclosed to the public and may be used. The name of the patch is 5d8515842fd1ab2c3a9f2dde9ffca907aa334ea9. Upgrading the affected component is recommended.

Published

Date2026-08-23

Updated

Date2026-08-23

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:N/I:P/A:N

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-78144

SUMMARY

A vulnerability was identified in code-projects Barangay Resident Profiling Management System 1.0. Affected by this vulnerability is an unknown functionality of the file /boarders.php of the component Boarder Management Module. Such manipulation of the argument ID leads to authorization bypass. The attack can be executed remotely. The exploit is publicly available and might be used.

Published

Date2026-08-23

Updated

Date2026-08-23

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-78143

SUMMARY

A vulnerability was determined in code-projects Barangay Resident Profiling Management System 1.0. Affected is an unknown function of the file residents.php of the component Resident Search Functionality. This manipulation of the argument Search causes sql injection. Remote exploitation of the attack is possible. The exploit has been publicly disclosed and may be utilized.

Published

Date2026-08-23

Updated

Date2026-08-23

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

CVE-2026-78142

SUMMARY

A vulnerability was found in code-projects Barangay Resident Profiling Management System 1.0. This impacts an unknown function of the file /archived_records.php of the component Restore/Delete. The manipulation of the argument resident_id results in authorization bypass. The attack may be launched remotely. The exploit has been made public and could be used.

Published

Date2026-08-23

Updated

Date2026-08-23

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…